Germline variant burden in multidrug resistance transporters is a therapy‐specific predictor of survival in breast cancer patients
Open Access
- 3 February 2020
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 146 (9) , 2475-2487
Abstract
Multidrug resistance due to facilitated drug efflux mediated by ATP‐binding cassette (ABC) transporters is a main cause for failure of cancer therapy. Genetic polymorphisms in ABC genes affect the disposition of chemotherapeutics and constitute important biomarkers for therapeutic response and toxicity. Here we correlated germline variability in ABC transporters with disease‐specific survival (DSS) in 960 breast cancer (BRCA), 314 clear cell renal cell carcinoma and 325 hepatocellular carcinoma patients. We find that variant burden in ABCC1 is a strong predictor of DSS in BRCA patients, whereas candidate polymorphisms are not associated with DSS. This association is highly drug‐specific for subgroups treated with the MRP1 substrates cyclophosphamide (log‐rank p = 0.0011) and doxorubicin (log‐rank p = 0.0088) independent of age and tumor stage, whereas no association was found in individuals treated with tamoxifen (log‐rank p = 0.13). Structural mapping of significant variants revealed multiple variants at residues involved in protein stability, cofactor stabilization or substrate binding. Our results demonstrate that BRCA patients with high variant burden in ABCC1 are less prone to respond appropriately to pharmacological therapy with MRP1 substrates, thus incentivizing the consideration of genomic germline data for precision cancer medicine.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (EXC 2180‐390900677)
- Horizon 2020 Framework Programme (668353)
- Vetenskapsrådet (2016‐01153, 2016‐01154)
This publication has 62 references indexed in Scilit:
- Quantitative Ultrasound Evaluation of Tumor Cell Death Response in Locally Advanced Breast Cancer Patients Receiving ChemotherapyClinical Cancer Research, 2013
- A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimenThe Pharmacogenomics Journal, 2012
- The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenalPharmacogenetics and Genomics, 2012
- ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patientsHaematologica, 2011
- Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with SunitinibClinical Cancer Research, 2011
- Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changesBritish Journal of Cancer, 2008
- Unbiased Recursive Partitioning: A Conditional Inference FrameworkJournal of Computational and Graphical Statistics, 2006
- Substrate recognition and transport by multidrug resistance protein 1 (ABCC1)FEBS Letters, 2005
- Molecular mechanisms of drug resistanceThe Journal of Pathology, 2005
- MDR1 Promoter Hypermethylation in MCF-7 Human Breast Cancer Cells: Changes in Chromatin Structure Induced by Treatment with 5-Aza-CytidineCancer Biology & Therapy, 2004